New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
13:38 EDTSHPG, C, NPSP, ABBV, BMY, GILD, BIIB, AMGNShire selects Citi as adviser to prepare for takeover offers, Reuters reports
Shire (SHPG) has hired Citi (C) as an adviser as it prepares for takeover bids, Reuters reports, citing sources. Bankers in the sector believe Shire could be a attractive to Bristol Myers (BMY), Abbvie (ABBV), Gilead (GILD), Biogen (BIIB) or Amgen (AMGN). Reference Link
News For SHPG;C;NPSP;ABBV;BMY;GILD;BIIB;AMGN From The Last 14 Days
Check below for free stories on SHPG;C;NPSP;ABBV;BMY;GILD;BIIB;AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 26, 2014
06:54 EDTCCitigroup, HSBC, others chosen to lead $3B ONGC stake sale, Reuters says
Subscribe for More Information
06:05 EDTGILDStocks with implied volatility movement; MCP GILD
Subscribe for More Information
August 25, 2014
16:17 EDTAMGNWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
16:00 EDTGILD, COptions Update; August 25, 2014
Subscribe for More Information
12:19 EDTGILDOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTGILDBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
09:35 EDTGILD, CActive equity options trading on open
Subscribe for More Information
06:11 EDTGILDStocks with implied volatility movement; FOLD GILD
Stocks with implied volatility movement; Amicus Therapeutics (FOLD) 87, Gilead (GILD) 25 according to iVolatility.
August 22, 2014
12:39 EDTBMY, BIIBThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
11:17 EDTGILDOptions Update; August 22, 2014
Subscribe for More Information
09:36 EDTGILD, CActive equity options trading on open
Subscribe for More Information
06:12 EDTCCitigroup faces restrictions on hedge-fund sales, WSJ reports
Subscribe for More Information
August 21, 2014
15:16 EDTABBVDEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
10:02 EDTCActive calls at CBOE; AAPL C HPQ
Active calls at CBOE; AAPL 8/22/14 100 & 100, C Jan 55, HPQ 8/29/14 36
07:57 EDTABBV, GILDGilead HCV risks overblown, says Bernstein
Bernstein believes that investors are concerned about upcoming competition to Gilead's (GILD) HCV drug from AbbVie's (ABBV) HCV treatment. But Bernstein says that insurers can only prevent 16% of the U.S. population from receiving Gilead's drug, and the firm does not expect the HCV market share dynamics to change in the near-term. It keeps an Outperform rating on Gilead.
06:43 EDTCRegulators up bank warning efforts for poor risk assessment, Reuters says
Subscribe for More Information
August 20, 2014
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
06:17 EDTCCitigroup looks to sell Japanese retail banking unit, Reuters says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use